Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Arch Med Res ; 51(7): 664-669, 2020 10.
Artículo en Inglés | MEDLINE | ID: mdl-32654881

RESUMEN

AIM/BACKGROUND: Although many agents have been tested as treatment options for caustic esophageal burn (CEB), none have successfully suppressed the formation of strictures. Thus,the purpose of this study was to determine the efficacy of Contractubex® gel (10% onion extract, 50 U/gr heparin, and 1% allantoin) in stricture preventing after CEB. METHODS: In this study, 24 Wistar-albino rats were divided into 4 groups. CEB was initiated with an instillation of 1 mL of 10% NaOH solution into the an isolated esophageal segment for 3 min. Group C (control) was uninjured and untreated. In Group CEB, was initiated but no treatment was given. In Groups CTX1 and CTX2, the animals received 100 and 200 mg/kg/d, respectively, of Contractubex® for 4 weeks via gavage after CEB was initiated. The stenosis indices (SI), histopathologic damage scores, tissue hydroxyproline (HP) levels, and weights of the rats were taken before the experiment and 4 weeks after the experiment. RESULTS: The Mean SI levels, HP levels, and histopathologic damage scores were statistically lower in Groups CTX1 and CTX2 when compared with Group CEB (p <0.05). The treatment groups increased in weight when compared to Group CEB. The results were similar between Group CTX1 and Group CTX2 (p >0,05); the efficacy of the treatment was not dose-dependent. CONCLUSION: For the first time, Contractubex® was used for its antifibrotic, antioxidant, anti-inflammatory, and wound healing effects to treat caustic esophageal burn in rats. It was effective in reducing stricture formation by decreasing the HP levels and histopathologic damage as well as preventing stenosis and weight gain in the treatment groups.


Asunto(s)
Alantoína/uso terapéutico , Quemaduras Químicas/tratamiento farmacológico , Constricción Patológica/tratamiento farmacológico , Estenosis Esofágica/tratamiento farmacológico , Heparina/uso terapéutico , Extractos Vegetales/uso terapéutico , Alantoína/farmacología , Animales , Quemaduras Químicas/patología , Modelos Animales de Enfermedad , Combinación de Medicamentos , Heparina/farmacología , Masculino , Extractos Vegetales/farmacología , Ratas , Ratas Wistar
2.
Pan Afr Med J ; 26: 55, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28451032

RESUMEN

Laryngotracheoesophageal clefts (LTECs) are rare congenital defects that are often accompanied by additional anomalies. The major issues in the treatment of these patients are intraoperative exposure insufficiency, technical difficulty of the operation, and anesthesia problems originating from the respiratory tract. Problems originating from mechanical ventilation and respiratory tract, eating disorders and relapse of fistula are among the problems encountered following surgery. Most of the time, concomitant additional anomalies also worsen the clinical picture. It was our aim with these case reports to report our experience in two cases with Type IV LTEC ranging from the inoperable type IV LTEC due to additional anomalies mounted up to severe respiratory distress to the carina that we operated on with a single stage anterior cervicothoracic approach on its fifth day on life.


Asunto(s)
Anomalías Congénitas/patología , Atresia Esofágica/patología , Laringe/anomalías , Fístula Traqueoesofágica/patología , Anomalías Congénitas/cirugía , Atresia Esofágica/cirugía , Humanos , Recién Nacido , Laringe/patología , Laringe/cirugía , Masculino , Fístula Traqueoesofágica/congénito , Fístula Traqueoesofágica/cirugía
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA